Personalis, Inc. | LinkedIn (original) (raw)

About us

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California.

Industry

Biotechnology Research

Company size

201-500 employees

Headquarters

Fremont, California

Type

Public Company

Founded

2011

Specialties

NGS, Immuno-oncology, Tumor Profiling, Tumor/Normal Analysis, Immunogenomics, Personalized Cancer Vaccines, Immune Modulators, Tumor Escape, Tumor Microenvironment, HLA Typing, Neoantigens, Whole Exome, Whole Transcriptome, Machine Learning, and Neural Networks

Locations

Employees at Personalis, Inc.

Updates

23,058 followers
5d Edited
We’re excited to attend the 3rd Annual Liquid Biopsy Surveillance Summit in Boston from November 21-22! If you’re in Boston for the LBx Summit, check out a presentation by Travis Yates, PhD, Senior Field Applications Scientist, at Personalis, on day 2 (Nov 22) highlighting our ultra-sensitive MRD testing technology, NeXT Personal®. Dr. Yates will highlight how NeXT Personal improves detection of ctDNA at baseline, and during follow-up, with increased lead time over clinical relapse, and go in-depth on a number of groundbreaking clinical studies in #LungCancer and #BreastCancer. Let us know if you’d like to chat at the LBx Summit with our team (Dan Nicolson, Nancy Groot, Julie Meyer): https://bit.ly/4goxSSO.#PrecisionOncology #LiquidBiopsy #ctDNA #MRD
Personalis, Inc. reposted this

Associate Director, Document Control at Personalis, Inc.
6d
Earlier this month, I had a chance to celebrate #Diwali with my colleagues from Personalis, Inc.! This special event, also known as the “Festival of Lights” is celebrated widely by Hindus across the globe. The Festival’s name comes from the row (“avali”) of clay lamps (“deepa”) that are traditionally lit outside of homes symbolizing light that protects from spiritual darkness. Thank you to our organizers who coordinated this wonderful celebration event and guided us in various activities like lantern making, Mehndi, and Diya painting
We’re honored to be participating in the Stand Up To Cancer Innovation Summit in New York! We’re joining together with other leading experts in the field of cancer vaccines and cancer detection technologies to explore how combined approaches can bring significant promise for early detection and improved patient outcomes. Christelle Johnson, Ph.D., Associate Director, Field Applications Scientists, Personalis, is in attendance to discuss the clinical impact of an ultra-sensitive minimal residual disease (MRD) assay for early recurrence detection.#PrecisionOncology #MRD #CancerDetection #CancerVaccines #Sequencing #NGS #StandUptoCancer #SU2C
“The core of this technology is the advance in identifying patient progression.” Hear from Dr. Andrew Nixon from Duke Cancer Institute and Olga Alexeeva, MBA, Strategy Director, Personalis how NeXT Personal® is able to detect cancer progression earlier through the identification of circulating tumor DNA (ctDNA). For patients with cancer, the earlier you track the better prepared you can be.#PrecisionOncology #LiquidBiopsy #MRD #ctDNA
We’re proud to be a sponsor for the 3rd Annual Liquid Biopsy Surveillance Summit in Boston next month. This impactful event will bring together industry leaders and experts in minimal residual disease (MRD) and liquid biopsy technologies to discuss the latest advancements and clinical strategies. If you’ll be in attendance, make sure to check out a presentation by Travis Yates, PhD, Senior Field Applications Scientist, at Personalis, on day 2 highlighting our ultra-sensitive MRD testing technology, NeXT Personal®. Let us know if you’d like to chat at the LBx Summit: https://bit.ly/4goxSSO.#PrecisionOncology #LiquidBiopsy #ctDNA #MRD
We’re excited to be participating in the 62nd Annual Meeting of the Japan Society of Clinical Oncology (JSCO), PhD, Associate Director, Field Applications Scientists, Personalis, gave an informative presentation highlighting our flagship liquid biopsy platform, NeXT Personal®. NeXT Personal is an ultra-sensitive liquid biopsy assay designed to detect and monitor residual and recurrent disease (MRD) in cancer patients by detecting very small traces of circulating tumor DNA (ctDNA) in the blood. Want to learn more about NeXT Personal and our other innovative oncology solutions? Reach out to Kedar Hastak or Howard Pan at JSCO 2024! Reach out to us after JSCO: https://bit.ly/4goxSSO.#PrecisionOncology #LiquidBiopsy #MRD #ctDNA
“I think…one of the main advantages of this technology, and the ultra-sensitivity…NeXT Personal® offers, is to advance the lead time to help patients at a time before their cancer has already gotten to radiographic progression...” Dr. Andrew Nixon from Duke Cancer Institute discusses the Keylargo study, in which researchers utilized NeXT Personal to assess molecular progression in 36 patients with pembrolizumab-treated gastroesophageal cancer. In the study, NeXT Personal was able to detect small traces of ctDNA (as low as 1.5 PPM) to identify molecular progression at an earlier time. Discover more from the video.#PrecisionOncology #LiquidBiopsy #MRD #ctDNA #GastroesophagealCancer
Based on 2019 data, ~44% of US patients with cancer were eligible for immunotherapy treatment, but only <13% of patients responded to it. Ultra-sensitive MRD testing technology like NeXT Personal® can help clinicians track patient response to immunotherapy, and help inform whether the therapy is working. Learn more about our collaboration with Dr Rodrigo Toledo, PhD MBA from the Vall d'Hebron Institute of Oncology (VHIO) in which researchers used NeXT Personal to monitor patient response to immunotherapy. With our ultra-sensitive MRD test, researchers saw that patients attaining ctDNA clearance at any point during treatment had >3-times longer median progression-free survival (PFS) compared to those who remained ctDNA+. Discover more from the video.#PrecisionOncology #LiquidBiopsy #MRD #ctDNA #ImmunoTherapy

Join now to see what you are missing

Join now

Personalis, Inc. | LinkedIn (original) (raw)

About us

Locations

Employees at Personalis, Inc.

Updates

Join now to see what you are missing

Similar pages

Browse jobs

Funding